Home » News
Inclusion complex of butylphthalide sulfobutyl beta cyclodextrin sodium

Butylphthalide (NBP) can increase the levels of nitric oxide (no) and prostaglandin (PGI2) in cerebral vascular endothelium, reduce the vascular resistance of internal carotid artery, increase its blood flow, promote the increase of the number of microvessels around the infarcted area, and significa

The epidemic situation in the Indian capital is worsening and the number of cases is soaring

Since April, the epidemic situation in India has been out of control seriously, and more than 200000 people have been diagnosed with new coronavirus infection for several days in a row, which has led to an extreme shortage of antiviral drugs in the Indian market. Recently, the Indian government has

Toward the Development of an Injectable Dosage Form of Propofol: Preparation and Evaluation of Propofol–Sulfobutyl Ether 7‐β‐Cyclodextrin Complex

The objectives of the present study were to undertake activities toward the development of an aqueous‐based formulation of propofol (2,6‐diisopropyl phenol), using sulfobutylether 7‐β‐cyclodextrin (SBECD). Preformulation studies, including high performance liquid chromatography (HPLC) method

no photo
Fusen Pharmaceutical (01652. HK) joint venture with Jiangxi Kangde was granted the exclusive license to develop, produce and sell Docetaxel (Betadex Sulfobutyl Ether Sodium as solubilizer) injection

Fushen Pharmaceutical (01652. HK) announced that on February 10, 2021, Jiangxi Yongfeng Kangde Pharmaceutical Co., Ltd entered into a license agreement with Bica Biotechnology (Guangzhou) Co., Ltd with docetaxel (Betadex Sulfobutyl Ether Sodium as solubilizer).




Tel: +86-531-88916568
 Mail: enquiry@cydextrin.com
​​​​​​​ Address: Boxing Economic Development Zone, Binzhou, Shandong, China.


Contact us
© 2020 Shandong Binzhou Zhiyuan Biotechnology Co., Ltd. All rights reserved. Sitemap